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Abstract 17 
Low permeability of the urinary bladder epithelium, poor retention of the chemotherapeutic agents due 18 
to dilution and periodic urine voiding as well as intermittent catheterisations are the major limitations of 19 
intravesical drug delivery used in the treatment of bladder cancer. In this work, maleimide-functionalised 20 
poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles were 21 
developed. Their physicochemical characteristics, including morphology, architecture and molecular 22 
parameters have been investigated by means of dynamic light scattering, transmission electron 23 
microscopy and small-angle neutron scattering techniques. It was established that the size of 24 
nanoparticles was dependent on the solvent used in their preparation and molecular weight of PEG, for 25 
example, 105 ± 1 nm and 68 ± 1 nm particles were formed from PLGA20K-PEG5K in dimethyl sulfoxide 26 
and acetone, respectively. PLGA-PEG-Mal nanoparticles were explored as mucoadhesive formulations 27 
for drug delivery to the urinary bladder. The retention of fluorescein-loaded nanoparticles on freshly 28 
excised lamb bladder mucosa in vitro was evaluated and assessed using a flow-through fluorescence 29 
technique and Wash Out50 (WO50) quantitative method. PLGA-PEG-Mal nanoparticles (NPs) exhibited 30 
greater retention on urinary bladder mucosa (WO50 = 15 mL) compared to maleimide-free NPs (WO50 = 31 
5 mL). The assessment of the biocompatibility of PEG-Mal using the slug mucosal irritation test revealed 32 
that these materials are non-irritant to mucosal surfaces. 33 
Keywords: urinary bladder, intravesical drug delivery, PLGA-PEG, maleimide, nanoparticles, small-34 
angle neutron scattering, slug mucosal irritation test, mucoadhesion, Wash Out50 (WO50). 35 
  36 
 3 
1. Introduction 37 
Mucoadhesion can be described as the ability of materials to adhere to mucosal membranes for 38 
extended periods of time. Transmucosal drug administration is currently employed in ocular 39 
(conjunctival and corneal), nasal, pulmonary, oromucosal (buccal and sublingual), gastrointestinal, 40 
rectal, vaginal and intravesical drug delivery, and it offers an alternative to injections [1–6]. 41 
Transmucosal drug delivery provides numerous advantages, including (i) prolonged residence time of a 42 
dosage form and high density of blood vessels on mucosal surfaces ensure more efficient and rapid drug 43 
absorption; (ii) non-oral drug administration allows avoiding its potential degradation in the stomach and 44 
prevents hepatic first-pass metabolism; (iii) ease of drug administration and the possibility for quick 45 
termination of a therapy resulting in improved patient compliance; (iv) possibility of targeting particular 46 
body sites and tissues due to local administration; and (v) reduced administration frequency. 47 
Mucoadhesive dosage forms could be highly beneficial for local drug administration to treat posterior 48 
segment diseases of the eye [7,8], neurological disorders (via intranasal administration) [9,10], and 49 
genitourinary tract dysfunctions [11,12]. 50 
Intravesical drug delivery (IDD) refers to a direct administration of active pharmaceutical 51 
ingredients into the urinary bladder using a catheter inserted through the urethra. This technique is 52 
generally used to treat bladder-related disorders, such as bladder cancer (BC) and interstitial cystitis [13–53 
15]. However, the efficiency of this route of drug administration is limited due to dilution and wash out 54 
during periodical micturition resulting in poor retention of instilled therapeutic agents. Additionally, the 55 
need for frequent catheterisations with potential risks of irritation, inflammatory reactions and infections 56 
makes this procedure rather unpleasant for patients [16]. 57 
Mucoadhesive materials have the potential to improve the efficacy of IDD by prolonging the drug 58 
residence in the bladder. First generation (conventional) mucoadhesive materials are traditionally used 59 
as matrixes in many formulations for transmucosal drug delivery. These include hydrophilic polymers 60 
of natural and synthetic origin, such as chitosan, carbopols and cellulose derivatives [17–21]. The 61 
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adhesion of these macromolecules is due to their ability to interact with glycosylaminoglycans/mucins 62 
present on mucosal surfaces through non-covalent interactions such as hydrogen bonding, electrostatic 63 
attraction and chain entanglement. 64 
Andreas Bernkop-Schnürch [22] pioneered the use of thiolated polymers (thiomers) as the second 65 
generation of mucoadhesives. Well-established water-soluble polymers were modified with thiol 66 
functional groups using different chemical approaches to greatly enhance their mucoadhesive properties 67 
[23–25]. A few studies reported the use of thiolated mucoadhesives for IDD. For example, thiol-68 
functionalised chitosan nanoparticles have been used for IDD in an in vitro study using porcine urinary 69 
bladders [26,27]. The ability of these thiolated mucoadhesives to stay adhered on mucosal surfaces is 70 
due to the formation of inter-disulphide bridges via covalent interaction with cysteine residues present in 71 
mucins. 72 
Recently, our group has demonstrated that polymeric nanogels [28] and PEGylated liposomes [29] 73 
functionalised with maleimide groups exhibited excellent mucoadhesive properties to bovine 74 
conjunctival tissues and freshly excised porcine bladder mucosa, respectively. The ability of these 75 
formulations to retain on mucosal tissues, evaluated using a flow-through method, was found to be 76 
comparable to a well-known mucoadhesive chitosan. The excellent mucoadhesive performance of these 77 
novel advanced formulations is attributed to their ability to form covalent linkages with thiol groups 78 
present in the mucus via Michael-type addition reactions. Later, other researchers have also reported the 79 
development of alginate- and chitosan-based mucoadhesives functionalised with maleimide groups and 80 
demonstrated their superior retention/adhesion on/to mucosal surfaces compared to unmodified 81 
polysaccharides [30, 31]. All the maleimide-functionalised systems reported so far [28–31] due to their 82 
hydrophilic nature were only suitable for formulation of water-soluble drugs. There is also a strong need 83 
in the development of mucoadhesive drug delivery systems capable of incorporating poorly-soluble 84 
drugs, which will require the use of less polar polymers for their development. 85 
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Poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG), a block copolymer 86 
approved by the US Food and Drug Administration, has been widely employed in controlled release 87 
formulations and tissue engineering applications due to its safety, low toxicity, low immunogenicity, 88 
high cytocompatibility and biodegradability [32]. PLGA-PEG could easily be self-assembled to micelles 89 
or nanoparticles by either simple single emulsion (oil-in-water) or double emulsion solvent evaporation 90 
(water/oil/water) techniques [33,34]. For instance, Bazylińska et al. [35] described the influence of 91 
preparation parameters, the type of polymer and active cargo on the colloidal and biological stability of 92 
final nano-carriers for further in vitro and in vivo applications. Pei et al. developed the application of pH-93 
sensitive intravenous PLGA-PEG formulations to deliver vancomycin in the therapy against intracellular 94 
pathogens [36]. PLGA-PEG nanoparticles functionalised with maleimide groups were also recently 95 
reported as carriers for drug delivery. Their maleimide-functionalised surface was used for further 96 
modification with monoclonal antibody [37] and cell penetrating peptides [38]. 97 
In the present work, we report the design of maleimide-functionalised PLGA-PEG nanoparticles 98 
as potential mucoadhesive formulations for IDD to urinary bladder and demonstrate that surface 99 
maleimide groups could significantly enhance mucoadhesive properties of these materials. Four types of 100 
nanoparticles were developed using PLGA-PEG containing 3 and 5 kDa PEG with and without 101 
maleimide terminal groups. The structural features of these nanoparticles were studied using small-angle 102 
neutron scattering, dynamic light scattering and transmission electron microscopy. The hydrophobic 103 
nature of PLGA-based core of the nanoparticles provided an excellent opportunity for formulating poorly 104 
water-soluble compound as a model drug. These nanoparticles were loaded with lipophilic fluorescein 105 
and their retention on urinary bladder mucosa was studied in vitro. Slug mucosal irritation in vivo test 106 
was used to assess the biocompatibility of PEG-Mal present on the surface of these nanoparticles. 107 
 108 
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2. Materials and methods 109 
2.1. Materials 110 
Four different di-block copolymers of poly(lactide-co-glycolide)-poly(ethylene glycol) ((methoxy-111 
terminated: Mw 20,000 : 3,000 Da, PDI 1.30 (PLGA20K-PEG3K) and Mw 20,000 : 5,000 Da, PDI 1.65 112 
(PLGA20K-PEG5K); maleimide-functionalised: Mw 20,000 : 3,400 Da, PDI 2.70 (PLGA20K-PEG3K-Mal) 113 
and Mw 20,000 : 5,000 Da, PDI 2.42 (PLGA20K-PEG5K-Mal)) were purchased from PolySciTech
® Akina 114 
Inc. (West Lafayette, IN, USA; catalogue numbers: AK101, AK037, AI109, AI020). Dimethyl sulfoxide 115 
(DMSO) was purchased from Fisher Scientific (Loughborough, UK), acetone and deuterium oxide 116 
(D2O), benzalkonium chloride (BAC), poly(ethylene glycol) methyl ether (PEG; average Mn 5,000 Da), 117 
methoxypolyethylene glycol maleimide (PEG-Mal; average Mn 5,000 Da) and phosphate buffered saline 118 
tablets (PBS) were purchased from Sigma-Aldrich (Gillingham, UK). 6-Maleimidohexanoic acid was 119 
purchased from Alfa Aesar (Heysham, UK). Fluorescein was purchased from Acros Organics (Geel, 120 
Belgium). All other chemicals were of analytical grade and used as received. 121 
2.2. Preparation of nanoparticles 122 
Empty and fluorescein-loaded PLGA-PEG nanoparticles were prepared via one-step 123 
nanoprecipitation (single emulsion) technique followed by dialysis. In brief, 20 mg of polymers and 1 124 
mg fluorescein were dissolved in 1 mL of DMSO or acetone to form organic phase. The organic phase 125 
was then added to 30 mL of deionised water dropwise under constant stirring to form a colloidal 126 
suspension, which was allowed to stir gently for 1 h. Finally, this suspension was purified by dialysis 127 
against deionised water (5L; 4 changes) using a dialysis membrane tube (molecular weight cut-off 12–128 
14 kDa; Medicell Membranes Ltd., UK) to remove residual solvent, filtered using 0.22 µm Minisart® 129 
syringe filters and stored in a fridge for further use. 130 
2.3. Particle size and zeta potential analysis 131 
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The size of fluorescein-free PLGA-PEG nanoparticles, their polydispersity index (PDI) and zeta-132 
potential values were determined using dynamic light scattering (DLS) at a scattering angle of 173° with 133 
a Zetasizer Nano-NS (Malvern Instruments, UK). Each nanoparticle dispersion was diluted 100-fold with 134 
ultra-purified water. Refractive index of 1.59 and absorbance of 0.01 were used in all measurements. 135 
Each sample was analysed three times at 25 °C and the Z-average mean ± standard deviation values were 136 
calculated. 137 
2.4. Transmission electron microscopy (TEM) 138 
Nanoparticles were imaged using a JEOL 2100 Plus TEM operated at an acceleration voltage of 139 
200 kV. Specimens were prepared by pipetting a drop of purified nanoparticle suspension (about 0.5 140 
mg/mL) onto a parafilm. A glow-discharged holey carbon film-coated 400-mesh copper grid was then 141 
placed onto the drop with “carbon” side and left in contact with the sample for 60 sec. The excess solution 142 
was removed by blotting with a filter paper. Then, a drop of 2% (w/v) uranyl acetate (UA) solution was 143 
deposited onto the parafilm and the grid remained in contact with “carbon” side with UA for another 60 144 
sec. The excess stain was removed by dabbing similarly as above and the sample was left to dry in air 145 
prior to TEM characterisation. This sample preparation technique was previously reported to give good 146 
quality of images for PLGA-PEG nanoparticles [39]. 147 
2.5. Small-Angle Neutron Scattering (SANS) study 148 
PLGA-PEG nanoparticles were prepared as described above. Briefly, 10 mg of polymers were 149 
dissolved in 1 mL of organic solvent (acetone or DMSO). This solution was then added to 20 mL of D2O 150 
dropwise under continuous stirring to form suspension of nanoparticles, which was then allowed to stir 151 
gently for an additional 20 min. Finally, 2 mL of aliquot was aspirated from the suspension and dialysed 152 
using a Spectra-Por® Float-A-lyzer® G2 dialysis membrane, with a molecular weight cut-off 3.5–5 kDa, 153 
against D2O to remove residual solvent, filtered using 0.22 µm Minisart
® syringe filters and stored in a 154 
fridge prior to SANS studies. 155 
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SANS experiments were performed at MLZ (Garching, Germany) on KWS-2 instrument [40]. 156 
Measurements were made on a 3He tubes array detector (144 tubes, pixel size 8 mm) using a non-157 
polarised, monochromatic (wavelength 𝜆 set by a velocity selector) incident neutron beam collimated 158 
with rectangular apertures for two sample-to-detector distances, namely 2, 8, and 20 m (𝜆 =  0.6 nm). 159 
With this setup, the investigated 𝑞-range was 0.015 nm-1 to 4.6 nm-1. In all cases, the two-dimensional 160 
scattering patterns were isotropic and were azimuthally averaged, resulting in the dependence of the 161 
scattered intensity 𝐼𝑠(𝑞) on the momentum transfer 𝑞 = 4𝜋𝑠𝑖𝑛𝜃/𝜆, where 2𝜃 is the scattering angle. The 162 
curves were corrected for background scattering from the empty cell and for detector efficiency. Hellma® 163 
Analytics Suprasil® 300 high precision quartz cells of 1 and 2 mm thickness were used for experiments. 164 
SANS experiments were performed in D2O solution. The D2O solution was measured and properly 165 
subtracted. The concentration of nanoparticles used in SANS measurements was 0.5 mg/mL. 166 
2.6. SANS data fitting 167 
The scattered intensity curves were fitted using the model of sphere with attached Gaussian chain 168 
having self-avoiding walk statistics implemented in SASFit software [41] based on the model developed 169 
by Pedersen et al. [42] (Fig. 1). 170 
The scattering curves in D2O could be fitted using the following function: 171 
𝐼(𝑞) = 𝑃𝑠𝑔𝑐(𝑞)𝑆(𝑞)          (1) 172 
We assume that 𝑆(𝑞) = 1 due to low concentration of nanoparticles in solution, 1 mg/mL. The 173 
overall scattering intensity of the sphere with attached Gaussian chain written as: 174 
𝑃𝑠𝑔𝑐 = 𝑁𝑎𝑔𝑔
2 𝛽𝑐𝑜𝑟𝑒
2 𝑃𝑐𝑜𝑟𝑒(𝑞) + 𝑁𝑎𝑔𝑔𝛽𝑏𝑟𝑢𝑠ℎ
2 𝑃𝑏𝑟𝑢𝑠ℎ(𝑞) + 2𝑁𝑎𝑔𝑔
2 𝛽𝑐𝑜𝑟𝑒𝛽𝑏𝑟𝑢𝑠ℎ𝑆𝑏𝑟𝑢𝑠ℎ−𝑐𝑜𝑟𝑒(𝑞) +175 
𝑁𝑎𝑔𝑔(𝑁𝑎𝑔𝑔 − 1)𝛽𝑏𝑟𝑢𝑠ℎ




2 𝑃𝑐𝑜𝑟𝑒(𝑞) is self-correlation term of the core; 𝑁𝑎𝑔𝑔𝛽𝑏𝑟𝑢𝑠ℎ
2 𝑃𝑏𝑟𝑢𝑠ℎ(𝑞) is self-correlation 177 
term of the chains; 2𝑁𝑎𝑔𝑔
2 𝛽𝑐𝑜𝑟𝑒𝛽𝑏𝑟𝑢𝑠ℎ𝑆𝑏𝑟𝑢𝑠ℎ−𝑐𝑜𝑟𝑒(𝑞) is the cross-term between the core and chains and 178 
𝑁𝑎𝑔𝑔(𝑁𝑎𝑔𝑔 − 1)𝛽𝑏𝑟𝑢𝑠ℎ
2 𝑆𝑏𝑟𝑢𝑠ℎ−𝑏𝑟𝑢𝑠ℎ(𝑞) is the cross-term between different chains. 𝑁𝑎𝑔𝑔 is the 179 
aggregation number of polymers forming the nanoparticle per surface area, 𝛽𝑏𝑟𝑢𝑠ℎ = 𝑉𝑏𝑟𝑢𝑠ℎ(𝜂𝑏𝑟𝑢𝑠ℎ −180 
𝜂𝑠𝑜𝑙𝑣) and 𝛽𝑐𝑜𝑟𝑒 = 𝑉𝑐𝑜𝑟𝑒(𝜂𝑐𝑜𝑟𝑒 − 𝜂𝑠𝑜𝑙𝑣) are the excess scattering lengths of a block in the corona and in 181 
the core, respectively. 𝑉𝑏𝑟𝑢𝑠ℎ and 𝑉𝑐𝑜𝑟𝑒 are the total volume of a block in the corona and in the core, 182 
respectively. 𝜂𝑏𝑟𝑢𝑠ℎ and 𝜂𝑐𝑜𝑟𝑒 are the corresponding  scattering length densities (SLDs). 𝑃𝑐𝑜𝑟𝑒(𝑞) is 183 
scattering of spherical core 184 
𝑃𝑐𝑜𝑟𝑒(𝑞, 𝑅𝑐𝑜𝑟𝑒) = 3
(sin(𝑞𝑅𝑐𝑜𝑟𝑒)−𝑞𝑅𝑐𝑜𝑟𝑒𝑐𝑜𝑠(𝑞𝑅𝑐𝑜𝑟𝑒))
(𝑞𝑅𝑐𝑜𝑟𝑒)3
       (3) 185 
The scattering intensity for the brush is given by: 186 
𝑃𝑏𝑟𝑢𝑠ℎ(𝑞, 𝑅𝑔𝑐ℎ𝑎𝑖𝑛) = 2
𝑒𝑥𝑝(−𝑥)−1+𝑥
𝑥2
         (4) 187 
where 𝑥 = 𝑅𝑔𝑐ℎ𝑎𝑖𝑛
2 𝑞2; 𝑅𝑔𝑐ℎ𝑎𝑖𝑛 is the gyration radius of a polymer chain. 188 
The contribution of cross term between core and chains which form brush of wormlike micelle is 189 
calculated using equation: 190 
𝑆𝑏𝑟𝑢𝑠ℎ−𝑐𝑜𝑟𝑒(𝑞, 𝑅𝑐𝑜𝑟𝑒, 𝑅𝑔𝑐ℎ𝑎𝑖𝑛, 𝑑) = 𝜓(𝑞𝑅𝑔𝑐ℎ𝑎𝑖𝑛)𝑃𝑐𝑜𝑟𝑒(𝑞, 𝑅𝑐𝑜𝑟𝑒)
𝑠𝑖𝑛(𝑞[𝑅𝑐𝑜𝑟𝑒+𝑑𝑅𝑔𝑐ℎ𝑎𝑖𝑛])
𝑞[𝑅𝑐𝑜𝑟𝑒+𝑑𝑅𝑔𝑐ℎ𝑎𝑖𝑛]




 is the form factor amplitude of the chain. 192 
The contribution of cross term between chains is calculated using equation: 193 






   (6) 194 
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where 𝑑 is parameter that accounts for non-penetration of the chains into the core and should be 195 
mimicked by 𝑑~1 for 𝑅𝑐𝑜𝑟𝑒 ≫ 𝑅𝑔𝑐ℎ𝑎𝑖𝑛. 196 
The model has the following fitting parameters: 𝑅𝑐𝑜𝑟𝑒 – core radius; 𝑉𝑐𝑜𝑟𝑒 – molecular volume of 197 
single block unit in the micellar core; 𝑉𝑏𝑟𝑢𝑠ℎ – molecular volume of single block unit in the micellar 198 
corona; 𝜂𝑐𝑜𝑟𝑒 – scattering length density of spherical core; 𝜂𝑏𝑟𝑢𝑠ℎ – scattering length density of the block 199 
unit in the corona; 𝜂𝑠𝑜𝑙𝑣 – scattering length density of solvent; 𝑅𝑔𝑐ℎ𝑎𝑖𝑛 – gyration radius of polymer 200 
chains in the corona; 𝐿 – contour length of polymer chain, 𝑏 – Kuhn segment length. 201 
Excess scattering lengths of solvent and polymeric shell, 𝑉𝑐𝑜𝑟𝑒, 𝑉𝑏𝑟𝑢𝑠ℎ, contour length of polymer 202 
chain, Kuhn segment length were known from literature data and polymer composition and were chosen 203 
to be fixed during the fitting procedure. 204 
To account for nanoparticles polydispersity, a Schulz-Zimm distribution of 𝑅𝑐𝑜𝑟𝑒 with 205 

















− 1           (8) 208 
The gyration radius 𝑅𝑔 of nanoparticles was calculated from Guinier regime to evaluate the overall 209 
size of nanoparticles. 210 
2.7. Encapsulation efficiency and loading capacity 211 
Amicon® Ultra-0.5 Ultracel-3 centrifugal filter unit with a molecular weight cut-off 10 kDa was 212 
used in these experiments. Each centrifugal filter device was pre-rinsed with PBS (500 µL) at 13,000 213 
rpm (7558 × g) for 30 min prior to further use. The dispersion of PLGA-PEG nanoparticles (500 μL) was 214 
placed in an ultrafiltration tube and centrifuged at 4 °C at 13,000 rpm (7558 × g) for 30 min. This loading 215 
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step was repeated twice. The filtrate was discarded and the retentate was washed with 250 μL of PBS by 216 
further centrifugation at 4 °C at 13,000 rpm (7558 × g) for 20 min. The filtrate was withdrawn again and 217 
the fluorescein-loaded PLGA-PEG nanoparticles in the retentate were then mixed with 100 μL DMSO 218 
(left for 6 h in a fridge to dissolve the nanoparticles and model drug) and spun at 4 °C at 13,000 rpm 219 
(7558 × g) for 10 min. The amount of free fluorescein in the supernatant was quantified using a Varian 220 
Cary Eclipse fluorescence spectrophotometer at 𝜆𝑒𝑥𝑐𝑖𝑡𝑎𝑡𝑖𝑜𝑛 and 𝜆𝑒𝑚𝑖𝑠𝑠𝑖𝑜𝑛 = 460 and 513 nm, respectively, 221 
and the encapsulation efficiency (EE%) and loading capacity (LC%) were determined using the 222 
following formulae: 223 
𝐸𝐸% =  
𝐶
𝐶𝑖
 × 100          (9) 224 
𝐿𝐶% =  
𝐶
𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑁𝑃𝑠
 × 100        (10) 225 
where 𝐶 is the amount of fluorescein encapsulated in the nanoparticles (NPs), and 𝐶𝑖 is the initial amount 226 
of fluorescein. A standard curve was generated by plotting the fluorescence intensities from different 227 
concentrations of the model drug and used to calculate EE% and LC% can be found in Supplementary 228 
Information (Fig. S1). 229 
2.8. Toxicology: slug mucosal irritation test 230 
The slug mucosal irritation test (SMIT) was carried out according to our previously published 231 
report [43]. Arion lusitanicus slugs were collected locally in Harris Garden (Reading, UK) and were 232 
housed in specially designed plastic containers and fed with lettuce, cabbage, carrots and cucumber. Each 233 
slug’s body lining was carefully examined and only slugs showing no evidence of macroscopic injuries 234 
with clear tubercles and a foot surface were used for testing purposes. Slugs weighing between 15 and 235 
23 g were isolated from the culture and were kept individually in 1.5 L glass beakers lined with a paper 236 
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towel soaked with 20 mL of PBS solution and left at room temperature for 48 h before the start of an 237 
experiment. All beakers were covered with a cling film pierced with tiny holes in order to allow air 238 
exchange. Each slug was individually weighed before the experiment and then placed in 90 mm Petri 239 
dishes lined with Whatman™ filter paper moistened with either positive/negative controls (2 mL of 1% 240 
BAC prepared in PBS and 2 mL of PBS solution, respectively) or 2 mL of each test materials (PEG, 241 
PEG-Mal and MHA) with the following concentrations: 0.00003; 0.0003; 0.003 and 0.03 mmol prepared 242 
in PBS. After 60 min contact period slugs were taken out, rinsed with 10 mL of PBS, gently wiped with 243 
the paper towel and then reweighed. The percentage of mucus production (MP%) was estimated as a slug 244 




 × 100         (11) 246 
where 𝑚𝑏 and 𝑚𝑎 are the weights of a slug before and after experiment, respectively. Each experiment 247 
was repeated 7 times using different slugs and the results were evaluated statistically, calculating the 248 
mean ± standard deviation values. 249 
2.9. Preparation of artificial urine solution 250 
Artificial urine solution was prepared according to the previously reported protocol [44]. Briefly, 251 
the following components were dissolved in deionised water by stirring overnight at room temperature, 252 
before making the total volume to 2000 mL: urea (24.27 g), uric acid (0.34 g), creatinine (0.90 g), sodium 253 
citrate dihydrate (Na3C6H5O7 ∙ 2H2O, 2.97 g), sodium chloride (NaCl, 6.34 g), potassium chloride (KCl, 254 
4.50 g), ammonium chloride (NH4Cl, 1.61 g), calcium chloride dihydrate (CaCl2 ∙ 2H2O, 0.89 g), 255 
magnesium sulfate heptahydrate (MgSO4 ∙ 7H2O, 1.00 g), sodium bicarbonate (NaHCO3, 0.34 g), sodium 256 
oxalate (Na2C2O4, 0.03 g), sodium sulphate (Na2SO4, 2.58 g), sodium phosphate monobasic monohydrate 257 
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(NaH2PO4 ∙ H2O, 1.00 g), and sodium phosphate dibasic (Na2HPO4, 0.11 g). The artificial urine solution 258 
(pH 6.40) was kept at 37 °C throughout the experiments. 259 
2.10. In vitro retention studies on lamb urinary bladder mucosa 260 
The retention of PLGA-PEG nanoparticles on lamb urinary bladder tissues in vitro was determined 261 
using a protocol previously described by our group with minor modifications [29]. Lamb bladder tissues 262 
were received from P.C. Turner Abattoirs (Farnborough, UK) immediately after animal slaughter, 263 
packed, frozen and transported in an insulated plastic container. The tissues were subsequently thawed 264 
upon arrival and carefully excised to yield approximately 2 × 3 cm sections, avoiding contact with the 265 
internal mucosa, which were then used in the experiments. The dissected bladder tissue was mounted on 266 
a glass slide with mucosal side facing upward and rinsed with 3 mL of artificial urine (AU; pH 6.40) 267 
solution. Experiments were performed with the bladder tissues maintained at 37 °C in an incubator. 268 
Aliquots (200 μL) from fluorescein-loaded PLGA-PEG nanoparticle stock solutions were withdrawn and 269 
deposited onto a mucosal surface and rinsed with AU at a constant flow rate of 2 mL/min using a syringe 270 
pump (total washing time was 50 min). Fluorescence images of a bladder tissue were taken using Leica 271 
MZ10F stereo-microscope (Leica Microsystems, UK) with Leica DFC3000G digital camera at 1.6× 272 
magnification with 30 ms exposure time (gain 2.0×), fitted with a GFP filter. The microscopy images 273 
were then analysed with ImageJ software by measuring the pixel intensity after each irrigation with AU. 274 
The pixel intensity of the blank samples (bladder mucosa without test material) were subtracted from 275 
each measurement and data are converted into numbers. All measurements were conducted in triplicate. 276 
Evaluation of formulations retention on the mucosa in vitro was quantified through WO50 values, 277 
which represent the volume of a biological fluid necessary to wash out 50 % of a mucoadhesive excipient 278 
from a substrate [45]. WO50 values of test materials were calculated via extrapolation of the average 279 
wash-off profiles to 50% using polynomial fitting (5th order) and Wolfram Alpha (a computational 280 
knowledge engine). 281 
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2.11. Statistical analysis 282 
Statistical analysis of data, i.e. mean values ± standard deviations were calculated and assessed for 283 
significance using two-tailed Student’s t-test and a one-way analysis of variance (ANOVA) followed by 284 
Bonferoni post hoc test using GraphPad Prism software (version 7.0), where p < 0.05 was fixed as the 285 
statistical significance criterion. 286 
3. Results and discussion 287 
3.1. Preparation and characterisation of nanoparticles 288 
PLGA-PEG nanoparticles, with and without fluorescein, were formulated using single emulsion 289 
method and precipitated from acetone and DMSO. The detailed preparation procedure of nanoparticles 290 
is illustrated in Fig. 2. The average mean diameter of all PLGA-PEG nanoparticles precipitated from 291 
DMSO remained ~100 ± 1 nm on average regardless of the molecular weight of PEG moiety in block 292 
copolymers, whereas the nanoparticles precipitated from acetone displayed smaller values of 65 ± 1 nm 293 
and 80 ± 1 nm for PLGA-PEG and PLGA-PEG-Mal, respectively. We believe that the difference in the 294 
particle sizes might depend on the dielectric constant of organic solvent (acetone, ε = 21 and DMSO, ε 295 
= 47) and their miscibility with water during formation of nanoparticles in aqueous phase [46]. It is also 296 
interesting to compare our results with the study reported by Yang et al. [47], who prepared PLGA-PEG 297 
nanoparticles from acetone, acetonitrile and tetrahydrofuran. They reported the solvent effect on the 298 
particle size with formation of 154 ± 3, 134 ± 2 and 186 ± 4 nm of nanoparticles from acetone, acetonitrile 299 
and tetrahydrofuran, respectively. Our nanoparticles prepared from acetone are much smaller (65 ± 1 300 
nm), which shows the strong influence of other factors, including individual block molecular weights 301 
and particle preparation techniques. 302 
All nanoparticles prepared in the present study showed negative zeta-potential greater than –21 mV 303 
and had low polydispersity of less than 0.20, indicating the presence of a homogeneous population with 304 
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a narrow size distribution (Fig. 3). The physicochemical characteristics of PLGA-PEG nanoparticles are 305 
summarised in Table 1. 306 
Fluorescein was used as a model drug to demonstrate the potential application of PLGA-PEG 307 
nanoparticles in drug delivery to urinary bladder. Fluorescein (partition coefficient, logP = 3.35, [48]) 308 
was loaded into the nanoparticles by first preparing the model drug solution in the organic solvent 309 
followed by dissolution of polymers and further nanoprecipitation in deionised water. 310 
The size and morphology of nanoparticles were further confirmed by TEM analysis and 311 
microphotographs are displayed in Fig. 4. Uranyl acetate was used as a negative staining to achieve 312 
reasonable contrast. TEM analysis revealed the formation of homogeneous vehicles with well-dispersed 313 
spherically shaped core and shell structure of nanoparticles and the results are in good agreement with 314 
the data obtained by DLS measurements (Table 1). 315 
3.2. Nanoparticle structure 316 
Small-angle neutron scattering (SANS) was used to probe the nanoparticle architecture and 317 
determine their molecular parameters. The use of SANS allows to get more information about small 318 
particles compared to DLS method. The scattering intensity 𝐼(𝑞) curves for all nanoparticle solutions are 319 
presented in Fig. 5A and 5B. Several issues should be noted from the inspection of these scattering 320 
curves. First, all curves have monotonous behaviour with 𝑞; no additional maxima are observed. It is a 321 
typical manifestation of moderate or high polydispersity for compact objects. Second, all curves are 322 
similar in the middle and high 𝑞 ranges that implies similarity of all nanoparticles from inside 323 
disregarding preparation way and used solvent. The only difference between the scattering curves is 324 
visible in low 𝑞 range that is probably related to the difference in the aggregation number. To have a 325 
deeper information, the gyration radius values of nanoparticles in solution were calculated using Guinier 326 
approximation (Table 2). Comparison of gyration and hydrodynamic radii reveals that these two 327 
parameters are clearly correlated. In agreement with DLS data, the gyration radius value for PLGA-PEG 328 
 16 
and PLGA-PEG-Mal nanoparticles precipitated from DMSO is nearly the same and insensitive to the 329 
PEG molecular weight to the presence of maleimide groups (Table 2). In contrast, the gyration radius 330 
value of nanoparticles precipitated from acetone is higher for longer length of a PEG chain. The ratio of 331 
gyration and hydrodynamic radii 𝑅𝑔/𝑅ℎ have been known as the 𝜌 parameter that is sensitive to the 332 
architecture of nano-objects. It provides model-independent clue on spatial arrangement of a scattering 333 
object [49–53], its theoretical value is known for some simple models such as a hard sphere (𝜌 =334 
 0.775), Gaussian chain in 𝛩-solvent (𝜌 =  1.5), long rods (𝜌 >  2.0). The 𝜌 parameter value calculated 335 
for PLGA-PEG and PLGA-PEG-Mal nanoparticles precipitated from DMSO undoubtedly pointing out 336 
on a spherical symmetry and compact structure in agreement with TEM results presented above. The 337 
change from DMSO to acetone results in the formation of nanoparticles with more loose structure since 338 
they have higher 𝜌 parameter value. Increasing of PEG molecular weight leads to increase in 𝜌 value 339 
highlighting the enhanced branching structure for 5 kDa PEG nanoparticles made from acetone. We have 340 
to mention here that some of these systems have 𝜌 value that is below the lowest possible theoretical 341 
limit, 0.775. Nevertheless, low values were already reported in a variety of publications. The 𝜌 parameter 342 
fluctuates around 0.8, an average value for all types of nanoparticles justifying the choice of the fitting 343 
model described in Experimental Section. 344 
The scattering curves obtained for the D2O solutions can be well fitted with the “sphere with 345 
attached Gaussian chain having self-avoiding walk statistics” model, assuming a Schulz-Zimm 346 
distribution for core radius. The calculated structural parameters are presented in Table 2. 347 
The obtained value of the core radii and shell thickness are in the range of 12–24 nm, which is in 348 
agreement with the 𝑅ℎ as observed in the DLS measurements and TEM. In all series of nanoparticles 349 
prepared by precipitation from acetone and DMSO, 𝑅𝑔𝑐ℎ𝑎𝑖𝑛 increases with increase in PEG molecular 350 
weight (Table 2), whereas 𝑅𝑐𝑜𝑟𝑒 is much less sensitive to PEG chain length. 351 
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Our results corroborate with SANS studies of PLGA-PEG based block copolymers published 352 
previously [47,54–57] keeping in mind the difference in composition, molecular weights and methods of 353 
preparation. For example, PEO-PLGA-PEO [55] and PLGA-PEG-PLGA [56] triblock copolymers were 354 
investigated using SANS. Apart from the difference in composition, triblock vs diblock, the copolymers 355 
reported in these papers were different on other important aspects. The molecular weight, Mn, of PLGA 356 
block was much lower than the one in our case, 3,500 g/moL [55] and 1,170 g/moL [56], respectively. 357 
In both cases solutions were prepared by direct dissolving in D2O in contrast with solvent exchange 358 
method exploited in the present paper. Additionally, structure factor was involved in the fitting procedure 359 
since the triblock copolymer solution were in semi-diluted regime, 24 and 20 wt.% for PEO-PLGA-PEO 360 
and PLGA-PEG-PLGA, respectively. Applying the Percus-Yevick (PY) hard-sphere model to describe 361 
the structure factor and Global Indirect Fourier Transformation (GIFT) to describe the form factor of the 362 
micelles composed of PEO-PLGA-PEO at 30 °C, the authors obtained the following values for the radii 363 
of a core and shell, 5.9 and 2.5 nm, respectively [55]. The presence of a shell was also reported by 364 
Khorshid et al for flower-like micelles composed by PLGA-PEG-PLGA triblock copolymers [56]. SANS 365 
method successfully disseminates the internal structure of nanoparticles. The SANS experiments give a 366 
clear evidence of asymmetric ellipsoid nanoparticles for the copolymer with the PEG block (Mn = 1,000 367 
g/moL), whereas spherical micelles with core-shell topology is observed for the polymer with longer 368 
PEG central block (Mn = 1,500 g/moL). The core-shell cylinder and spherical shell models were utilised 369 
to fit the SANS data [56]. Unlike the PEO-PLGA-PEO system, both PLGA-PEG-PLGA copolymers 370 
were studied not only in semi-diluted but also for diluted concentration, 1 wt.%. The core and shell radii 371 
for PLGA1170-PEG1500-PLGA1170 were 5.0 nm and these values are much lower in comparison with the 372 
data reported in our manuscript, Rcore and Rgchain, Table 2, that is not surprising keeping in mind much 373 
higher molecular weights for PLGA and PEG of our copolymers. 374 
Interesting contrast variation SANS study was performed for laponite/PEG1.0k-PLGA0.8k and 375 
laponite/PEG1.0k-PLGA1.6k nanocomposites in a broad range of D2O/H2O mixture concentrations [57]. 376 
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It was found that for 66 % of D2O, the scattering from laponite is matched to the scattering of solvent. 377 
The combination of core-shell spherical model in combination with Debay form factor was used for the 378 
fitting the scattering profile from laponite free nanoparticles made of PEG-PLGA copolymers. The radius 379 
of a core and the micelles was found 1.6 and 4.7 nm, respectively, giving the shell thickness value to be 380 
of 3.1 nm [57]. We note here that the model used in our work is very close to the one reported in [57]. 381 
Two SANS studies that are the most relevant to our paper deal with nanoparticles composed from PLGA-382 
PEG [47] and PLA-PEG [54] diblock copolymers. In both papers, nanoparticles were prepared by solvent 383 
exchange method. The spherical model with a polydisperse core of constant scattering density and 384 
diffusive shell was applied for the fitting of PLA-PEG copolymers [54]. The fitting data reported for the 385 
acetone as the organic solvent and copolymer with similar composition PLA15600-PEG5000 are in perfect 386 
agreement with our results for PLGA20K-PEG5K (Table 2). The mean core radius of the nanoparticles 387 
made of PLA15600-PEG5000 is 11 nm, which correlates with our results, 12 nm. The Schultz-Zimm 388 
poldispersity values are almost identical, 0.27 [54] vs 0.21 in our study. The thickness of the PEG shell 389 
of 6.7 nm for PLA15600-PEG5000 also agrees well with our data for PLGA20K-PEG5K that was found to be 390 
6.9 nm. 391 
Surprisingly, the similar systems measured recently show clearly distinctive results [47]. The 392 
PLGA-PEG nanoparticles prepared by solvent exchange method presumably composed from micelles 393 
that form a fractal structure inside of a nanoparticle. One of the plausible explanations could be the 394 
existence of some residual reactive groups on PLGA-PEG copolymers reported in [47]. Such reactive 395 
groups might form bridges between PLGA-PEG micelles. 396 
The choice of the solvent used for precipitation has the greatest impact on nanoparticles structure. 397 
Interestingly, nanoparticles dissolved and precipitated from acetone have not only a smaller core but also 398 
lower 𝑅𝑔𝑐ℎ𝑎𝑖𝑛 value in comparison with the NPs precipitated from DMSO. This is a rather unpredicted 399 
result that might indicate a different local structure of the interface between PLGA core and PEG brush 400 
and different conformation of PEG chains. Indeed, the gyration radius of a PEG chain is twice lower for 401 
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NPs precipitated from acetone. Such striking difference could only be explained by compaction of PEG 402 
chains on the surface of nanoparticles precipitated from acetone and, in reverse, fully stretched PEG 403 
conformation in case of NPs made from DMSO. This hypothesis is indirectly supported by another 404 
peculiar feature observed from the SANS results fitting: the presence of maleimide terminal groups 405 
increases the 𝑅𝑔𝑐ℎ𝑎𝑖𝑛 for DMSO series, and in reverse, decreases 𝑅𝑔𝑐ℎ𝑎𝑖𝑛 for NPs precipitated from 406 
acetone (Table 2). We hypothesize that NPs prepared from DMSO have a narrow interface between 407 
PLGA and PEG blocks, whereas precipitation from acetone somehow facilitates the formation of the 408 
broad interface layer where PLGA and PEG coexist. Inevitably, bulky maleimide groups attached to the 409 
dangling PEG chains increase the gyration radius of PEG for NPs precipitated from DMSO. For NPs 410 
precipitated from acetone we might expect that some of Mal groups, due to hydrophobic nature of 411 
maleimide, will have tendency to incorporate into smooth PLGA-PEG interface (see inserts in Fig. 5). 412 
Provided that the nanoparticles precipitated from DMSO have the greatest presence of active maleimide 413 
groups on their surface, all subsequent experiments were performed with these samples. 414 
3.3. Mucosal irritancy 415 
The information about the biocompatibility and toxicological characteristics of maleimide-416 
containing materials is currently lacking in the literature. Previously, the biocompatibility of 417 
polysaccharides functionalised with maleimide groups was evaluated only by Shtenberg et al. [30] using 418 
normal human dermal fibroblasts and by Sahatsapan et al. [31] using human gingival fibroblast cells. 419 
The slug mucosal irritation test (SMIT) was developed by Adriaens et al. [58,59] to evaluate the 420 
mucosal irritancy potential of different formulations and active ingredients. It uses terrestrial slug species, 421 
which are considered to have limited sentience and so are not protected by regulations covering animal 422 
experiments [58]. Normally, slugs release mucus to aid their locomotion. They also produce mucus and 423 
lose body weight when in contact with irritating substrates. When their mucosal tissue is damaged the 424 
slugs release additional proteins and enzymes. This indication allows for quantifiable outcomes as for 425 
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irritants to be classified as non-irritating, mild or severely irritating. Generally, mild irritants cause an 426 
increase in mucus production, whereas severe irritants result in tissue erosion and more mucus release in 427 
addition to increased production [60]. 428 
Previously we reported the use of SMIT for assessing mucosal irritancy of 2-429 
hydroxyethylmethacrylate and 2-hydroxyethylacrylate based random copolymers of different 430 
compositions as well as blend films based on poly(acrylic acid) and methylcellulose using Limax flavus 431 
and Arion lusitanicus slugs [43,61]. In the present work, we have adopted the same methodology and 432 
used Arion lusitanicus slugs to evaluate the ability of model compounds PEG, PEG-Mal and 6-433 
maleimidohexanoic acid (MHA) to cause mucosal irritation. Fig. 6 presents the results on mucus 434 
production by slugs exposed to filter paper surfaces moistened with solutions of PEG, PEG-Mal and 435 
MHA of various concentrations prepared in PBS as well as positive and negative controls. In experiments 436 
with 1% solution of BAC in PBS (pH 7.50), used as a positive control, slugs experienced a severe 437 
discomfort, producing approximately 38 ± 7% of yellow mucus, whereas slugs exposed to PBS (used as 438 
a negative control, pH 7.74) did show a low level of mucus production of 5 ± 1%. These data are in good 439 
agreement with our previous studies [43,61]. A significant variability of the data obtained from 440 
experiments with positive control is explained by slugs’ increased activity and tendency to escape a 441 
contact with an irritant chemical. In all experiments with negative control and polymeric excipients slugs 442 
secreted colourless mucus, which is the first demonstration of their reasonably good biocompatibility. 443 
The concentration of test materials of 0.0003 mmol, used to prepare PLGA-PEG nanoparticles in 444 
dispersion, was chosen as a reference for the preparation of liquid formulations with model maleimide-445 
containing compounds (MHA and PEG-Mal). Filter paper soaked with 0.03 mmol MHA (pH 4.34) 446 
displayed significantly higher irritancy (p < 0.001) compared to PEG-Mal (0.03 mmol; MP 6 ± 2%; pH 447 
6.92) with the level of mucus production reaching 21 ± 7% and confirming the ability of MHA to irritate 448 
mucosal epithelia due to, mainly, its acidic nature (Fig. 6). Additionally, slugs exposed to positive control 449 
exhibited an extreme discomfort (p < 0.0001) compared to slugs in response to contact with 0.0003 mmol 450 
 21 
PEG-Mal. However, filter paper soaked with increasing concentrations of PEG and PEG-Mal 451 
demonstrated low irritation potential as no significant differences (p > 0.5) were observed between these 452 
materials and the negative control. Fig. S2 and Fig. S3 in Supplementary Information provide the detailed 453 
schematic illustration of SMIT test and the photographs of mucus production by Arion lusitanicus slugs 454 
exposed to various test chemicals, respectively. Safety, non-toxicity, and biocompatibility of PEG-Mal 455 
allows us to conclude that PLGA-PEG-Mal nanoparticles should not cause irritation in the bladder lining. 456 
The non-irritant nature of maleimide-functionalised materials established in this study is also in good 457 
agreement with the data reported by Shtenberg et al. [30], who reported that alginate modified with 458 
maleimide-terminated PEG is non-toxic to normal human dermal fibroblasts. The maleimide-459 
functionalised chitosan was also reported by Sahatsapan et al. [31] to be non-toxic to gingival fibroblast 460 
cells (HGF) up to 1000 μg/mL of polymer in solution. 461 
3.4. Mucoadhesion studies 462 
The retention properties of fluorescein-loaded PLGA-PEG and PLGA-PEG-Mal nanoparticles on 463 
lamb urinary bladder mucosa were evaluated using a flow-through method with fluorescent detection 464 
using the methodology described in our previously published paper [29]. Fig. 7 shows exemplary 465 
fluorescent images of the retention of PLGA-PEG and PLGA-PEG-Mal nanoparticle dispersions on 466 
urinary bladder mucosa irrigated with AU. After analysis of the fluorescent images using ImageJ 467 
software, it was established that maleimide-functionalised PLGA20K-PEG5K-Mal and PLGA20K-PEG3K-468 
Mal nanoparticles exhibited greater mucoadhesive properties compared to unmodified counterparts (p < 469 
0.001), confirming that PLGA-PEG-Mal nanoparticles adhere well to the bladder mucosa by forming 470 
covalent linkages with thiol groups present in mucin layer of the bladder epithelium (Fig. 8). Such 471 
selective binding leads to increased urothelium cell uptake and potentially improved drug bioavailability 472 
within the bladder wall. The nanoparticles remained on the bladder mucosa even after 50 min of washing 473 
with a cumulative AU volume of 100 mL. This is in good agreement with our previous findings [28,29], 474 
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therefore the results of retention study confirm the mucoadhesive properties of maleimide-functionalised 475 
PLGA-PEG nanoparticles, which could also be used as potential mucoadhesive drug carriers in IDD to 476 
urinary bladder. 477 
Previously we have introduced a novel quantitative method of evaluating and comparing the 478 
retention efficacy of liquid formulations on mucosal membranes through the use of WO50 values, which 479 
represent the volume of a biological fluid necessary to wash out 50 % of the mucoadhesive test material 480 
from a substrate [45]. In this study, we employed the same method and calculated WO50 values by 481 
analysing individual wash-off profiles for each nanoparticle suspensions and the results are presented in 482 
Table 1. By comparing these values for different PLGA-PEG nanoparticles used in this study, it is clear 483 
that PLGA20K-PEG5K-Mal have greater retention on lamb bladder mucosa (WO50 = 15 mL, R
2 = 1) 484 
compared to unmodified PLGA20K-PEG5K (WO50 = 5 mL, R
2 = 0.9872). 485 
4. Conclusions 486 
Four different types of PLGA-PEG nanoparticles were prepared and evaluated in this study for 487 
their physicochemical characteristics and retention on urinary bladder mucosa. The nanoparticles 488 
decorated with maleimide functional groups demonstrated greater retention on the bladder mucosa in 489 
vitro due to their ability to form covalent linkages with thiol groups of glycoproteins expressed on the 490 
bladder epithelial membrane. The biocompatibility of PEG-Mal was confirmed by SMIT assay 491 
experiments. 492 
The development of mucoadhesive drug delivery systems that could improve drug residence in the 493 
bladder will clearly be beneficial for the treatment of bladder cancer. However, all existing strategies to 494 
develop mucoadhesive materials do not provide dosage forms that could selectively bind to cancer cells 495 
without adhesion to healthy epithelial cells. The development of systems that could target cancer cells in 496 
the bladder is one of the challenges for future research and development in this area. 497 
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The maleimide-functionalised PLGA-PEG mucoadhesive nanoparticles developed in this work 498 
could potentially be considered as a platform technology that could be used for drug delivery not only to 499 
the bladder but also to other mucosal routes of drug administration. Further research will be focused on 500 
biodegradation of these nanoparticles and studies of anticancer drugs encapsulation and release. 501 
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GRAPHICAL ABSTRACT 713 
 714 
Schematic illustration depicting the mechanism of enhanced mucoadhesion of PLGA-PEG-Mal 715 
nanoparticles on urinary bladder mucosa. 716 
  717 
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FIGURES WITH CAPTIONS 718 
 719 
 720 
Fig. 1. The model used for the fitting of experimental SANS data. 721 
(single column fitting image)  722 
 34 
 723 
Fig. 2. Illustrative diagram depicting the preparation of PLGA-PEG nanoparticles with maleimide-724 
functionalised surface. 725 
(2-column fitting image)  726 
 35 
   727 
Fig. 3. Size distribution of PLGA-PEG (A) and PLGA-PEG-Mal (B) nanoparticles dissolved and 728 
precipitated from acetone and DMSO as determined by DLS. 729 
(2-column fitting image) 730 
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 731 
Fig. 4. TEM microphotographs of PLGA-PEG-Mal NPs dissolved and precipitated from acetone (A) and 732 
DMSO (B). Scale bars are 100 nm. 733 












































Fig. 5. SANS curves for PLGA-PEG nanoparticles dissolved and precipitated from acetone (A) and 736 
DMSO (B). Solid line is a fitting curve. Inserts: Proposed structures of nanoparticles. 737 
(2-column fitting image)  738 
 38 
 739 
Fig. 6. Mucus production by Arion lusitanicus slugs in response to 60 min exposure to PEG, PEG-Mal 740 
and MHA as well as positive (benzalkonium chloride – BAC) and negative (phosphate buffered saline – 741 
PBS) controls. Data are expressed as mean ± standard deviation (n = 7). Statistically significant 742 
differences are given as: **** – p < 0.0001; *** – p < 0.001; ns – no significance. 743 
(single column fitting image)  744 
 39 
 745 
Fig. 7. Exemplar fluorescence images showing retention of PLGA-PEG nanoparticles on lamb urinary 746 
bladder mucosa washed with different volumes of AU. Scale bars are 2 mm. 747 
(2-column fitting image)  748 
 40 
 749 
Fig. 8. Percentage retention of PLGA-PEG nanoparticles on lamb urinary bladder mucosa after irrigating 750 
with different volumes of AU solution. Data are expressed as mean ± standard deviation (n = 3). 751 
Statistically significant differences are given as: **** – p < 0.0001; *** – p < 0.001; ** – p < 0.01; ns 752 
– no significance. 753 
(single column fitting image)  754 
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TABLES WITH CAPTIONS 755 
Table 1. Physicochemical characteristics of PLGA-PEG nanoparticles. 756 
Formulation Solvent 








EE% LC% WO50 (mL)* 
PLGA20K-PEG3K 
DMSO 
94 ± 1 0.048 –20.8 ± 0.5 62.7 ± 3.6 3.1 ± 0.2 4; (R2 = 0.9860) 
PLGA20K-PEG5K 105 ± 1 0.070 –21.6 ± 0.4 63.8 ± 6.9 3.2 ± 0.4 5; (R2 = 0.9872) 
PLGA20K-PEG3K-Mal 98 ± 1 0.060 –17.7 ± 0.6 60.0 ± 4.2 3.0 ± 0.2 6; (R2 = 0.9931) 
PLGA20K-PEG5K-Mal 104 ± 1 0.067 –12.2 ± 0.5 55.0 ± 5.8 3.0 ± 0.3 15; (R2 = 1) 
PLGA20K-PEG3K 
Acetone 
64 ± 1 0.110 –8.1 ± 0.7 N/A N/A N/A 
PLGA20K-PEG5K 68 ± 1 0.248 –5.2 ± 0.6 N/A N/A N/A 
PLGA20K-PEG3K-Mal 80 ± 1 0.094 –16.5 ± 0.6 N/A N/A N/A 
PLGA20K-PEG5K-Mal 81 ± 1 0.206 –10.8 ± 0.8 N/A N/A N/A 
DMSO, dimethyl sulfoxide; PLGA-PEG, poly(lactide-co-glycolide)-block-polyethylene glycol); Mal, maleimide; PDI, polydispersity 757 
index; EE%, encapsulation efficiency; LC%, loading capacity; WO50, Wash Out 50% profile is a volume of artificial urine required to 758 
wash out 50% liquid formulation; N/A, not applicable. *Polynomial fitting (5th order) was used to quantify WO50 values. Results are 759 
given as mean ± standard deviation (n =3).  760 
(2-column fitting table)  761 
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Table 2. Comparison of structural parameters obtained from samples PLGA-PEG nanoparticles in D2O 762 





𝑅𝑐𝑜𝑟𝑒 (nm) σ 𝑅𝑔𝑐ℎ𝑎𝑖𝑛 (nm) 
PLGA20K-PEG3K 
DMSO 
35.7  1.4 0.76 14.8 ± 0.1 0.43 12.0 ± 0.1 
PLGA20K-PEG5K 40.8  1.5 0.78 15.4 ± 0.2 0.63 12.1 ± 0.3 
PLGA20K-PEG3K-Mal 35.7  0.9 0.73 14.6 ± 0.1 0.31 14.4 ± 0.2 
PLGA20K-PEG5K-Mal 35.5  0.7 0.68 15.8 ± 0.2 0.20 16.7 ± 0.3 
PLGA20K-PEG3K 
Acetone 
21.0  0.8 0.66 10.2 ± 0.2 0.33 6.9 ± 0.1 
PLGA20K-PEG5K 36.0  0.5 1.06 12.0 ± 0.2 0.21 8.6 ± 0.1 
PLGA20K-PEG3K-Mal 30.0  1.0 0.75 12.8 ± 0.1 0.50 4.1 ± 0.2 
PLGA20K-PEG5K-Mal 33.0  2.0 0.81 12.0 ± 0.1 0.24 8.3 ± 0.1 
DMSO, dimethyl sulfoxide; PLGA-PEG, poly(lactide-co-glycolide)-block-polyethylene glycol); Mal, maleimide; 𝑅𝑔, overall gyration 763 
radius of a nanoparticle; 𝑅𝑐𝑜𝑟𝑒, core radius; 𝜎, polydispersity parameter; 𝑅𝑔𝑐ℎ𝑎𝑖𝑛, gyration radius of a polymer chain in the corona. 764 
(single column fitting table) 765 
